Key Highlights

  • EPS ex-items of USD 0.16 rose 46% from the second quarter and matched the USD 0.16 consensus estimate.
  • Revenue of USD 132.1 million rose 6% sequentially, edging past the USD 131.87 million consensus estimate.
  • Reservoir Description revenue grew 7% to USD 84.3 million, while Production Enhancement revenue rose 4% to USD 47.8 million.
  • Free cash flow was USD 1.7 million, and net debt stood at USD 93.4 million at quarter end.

Core Laboratories Inc. (NYSE:CLB) reported third-quarter 2026 revenue of USD 132.1 million, up 6% from the second quarter, down 2% from a year earlier, and slightly above a consensus estimate of USD 131.87 million. Earnings per diluted share excluding items were USD 0.16, in line with a consensus estimate of USD 0.16, up 46% sequentially and down 27% year over year. On a GAAP basis, diluted earnings per share were USD 0.12, compared with USD 0.30 in the prior-year quarter.

Operating income was USD 12.1 million under GAAP and USD 12.6 million excluding items, a 10% operating margin with sequential incremental margins of 43%. The prior-year quarter's GAAP operating income of USD 20.9 million had included USD 5.6 million of other income, net. The effective tax rate was 41% in the quarter.

Segment Performance and Regional Trends

Reservoir Description revenue of USD 84.3 million rose 7% from the second quarter and fell 4% from a year earlier, with operating income of USD 8.1 million excluding items. About 80% of the segment's revenue comes from projects outside the United States. Growth came from Europe-Africa, Asia-Pacific, Latin America and the Middle East, where assay demand improved late in the quarter but stayed below levels seen before the regional conflict. CEO Larry Bruno also pointed to long-cycle offshore exploration and appraisal work and to rising activity across Asia-Pacific.

Production Enhancement revenue of USD 47.8 million rose 4% sequentially and 3% year over year, and operating income excluding items was USD 4.4 million. Product sales climbed 14% sequentially on stronger U.S. land completion demand and adoption of proprietary completion technologies, while delays to several large diagnostic projects in the Gulf of America weighed on service revenue and margins. Customer wins included an expanded Middle East unconventional reservoir program and a perforating technology rollout across a North American client.

Cash Flow, Leverage and Fourth-Quarter Guidance

Cash from operations was USD 5.0 million and capital expenditures were USD 3.3 million, producing free cash flow of USD 1.7 million. Working capital rose because of costlier raw materials for perforating systems and higher receivables as activity increased late in the quarter. Net debt was USD 93.4 million, a USD 0.2 million reduction, and the leverage ratio was under 1.50. The company repurchased 87,873 shares for about USD 1.1 million and approved a dividend of USD 0.01 per share payable on November 30, 2026.

For the fourth quarter, the company projects revenue of USD 128.5 million to USD 134.5 million, operating income of USD 10.7 million to USD 15.1 million, and EPS of USD 0.12 to USD 0.20, assuming a 25% tax rate. Management anticipates relatively flat sequential revenue because attacks early in the quarter affected Middle East client operations and delayed some projects.

Details Behind the Next Update

Four items frame the next report. Reservoir Description revenue is guided to USD 81.0 million to USD 85.0 million after USD 84.3 million this quarter. Production Enhancement revenue is guided to USD 47.5 million to USD 49.5 million, with operating income of USD 5.5 million to USD 6.7 million. EPS is guided to USD 0.12 to USD 0.20, against USD 0.16 ex-items now. Net debt of USD 93.4 million and return on invested capital of 5.9% under the company's chosen peer-comparison formula round out the balance sheet and returns picture.